Article Text

Download PDFPDF
CASE REPORT
Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma
  1. Nivedita Arora1,2,
  2. Arjun Gupta1,2,
  3. Navid Sadeghi2,3
  1. 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
  2. 2Parkland Health and Hospital System, Dallas, Texas, USA
  3. 3Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
  1. Correspondence to Navid Sadeghi, navid.sadeghi{at}utsouthwestern.edu

Summary

Plasmablastic lymphoma (PBL) is an aggressive form of non-Hodgkin’s lymphoma (NHL) classically seen in patients infected with the human immunodeficiency virus, but can also be seen in other immunocompromised states such as transplant recipients, autoimmune diseases and the elderly. PBL is generally associated with a poor prognosis despite chemotherapy. There is evidence supporting the use of bortezomib in combination with standard chemotherapy to achieve durable responses in patients with PBL. We describe a patient with acquired immunodeficiency syndrome who presented with rectal pain and bright red blood per rectum. He was diagnosed with stage IVA PBL with anorectal, nodal, calvarial and hepatic involvement. Along with highly active antiretroviral therapy, he was treated with six cycles of dose adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) plus bortezomib resulting in durable complete remission 30 months after diagnosis.

  • malignant and benign haematology
  • hiv / aids

Statistics from Altmetric.com

Footnotes

  • Contributors NA, AG and NS were involved in the conception and design, acquisition and analysis of data, drafting the article or revising it critically for important intellectual content and gave final approval of the version published.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.